The MASPAC study is investigating the benefit of MR-guided radiation of primary tumors between standard chemotherapy cycles for pain control and prevention in patients with metastatic ductal adenocarcinoma of the pancreas.
Aim of the study
We would like to find out whether highly precise and intensive radiation of the pancreatic tumor using stereotactic radiation therapy (SBRT), which is used in addition to standard combination chemotherapy, has a benefit in terms of reducing or preventing pain.
Who can take part?
Patients with metastatic ductal adenocarcinoma of the pancreas
Procedure
If you decide to take part, you will be randomly assigned to one of two groups. In group A ("intervention"), you will receive SBRT in addition to standard combination chemotherapy. In group B ("control") you will only receive combination chemotherapy. Important: Both groups are treated with standard chemotherapy. One group (B) directly, the other group (A) after completion of the SBRT.
Compensation
None
Original study name
MR-guided adaptive stereotactic body radiotherapy (SBRT) of the primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC) - a randomized controlled clinical trial
BASEC number
2021-01427
Financial support from
Munich University Hospital